ArticleNeurochemical research2026
RIP1 Exacerbates BBB Disruption by Impairing Autophagy-Mediated A2 Astrocyte Polarization in Hypertension-Induced Cerebral Microhemorrhage in Mice.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cerebral microhemorrhages (CMHs) contribute to cognitive decline and motor deficits. Inhibiting A1 astrocyte polarization can attenuate brain injury and promote recovery after experimental intracerebral hemorrhage. Despite RIP1 is a known mediator of neurological impairment in hemorrhage models, it is not known whether it regulates astrocytic phenotypic switching to influence CMH progression. Here, a mouse model of hypertension-induced CMHs was established by co-administration of Ang II and L-NAME. Following hypertension induction, daily neurological assessments showed progressively declining scores, indicating ongoing CMH development. RIP1 silencing delayed CMH onset, reduced cumulative incidence, and alleviated hypertension-induced deficits including gait abnormalities, impaired spatial learning and memory, blood-brain barrier (BBB) dysfunction, and A1 astrocyte polarization. In vitro, primary mouse astrocytes were exposed to hemoglobin to simulate the microhemorrhagic microenvironment. RIP1 silencing attenuated hemoglobin-induced A1 polarization and promoted a shift toward the A2 phenotype. Furthermore, RIP1 knockdown counteracted the detrimental effects of A1-polarized astrocytes on endothelial function, as evidenced by improved endothelial cell proliferation, migration, and tube formation. Mechanistically, RIP1 knockdown facilitated the transition from A1 to A2 astrocytic phenotype by activating autophagy and suppressing the NF-κB-NLRP3 inflammasome pathway, thereby mitigating hypertension-induced BBB disruption following CMHs. In conclusion, RIP1 silencing alleviates BBB disruption following hypertension-induced CMHs by promoting autophagy-mediated A2 astrocyte polarization.
Indexed as
Identifiers
41817888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.